Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

<p>Abstract</p> <p>Background</p> <p>The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxici...

Full description

Bibliographic Details
Main Authors: Nakano Kazuhiko, Ohta Shigeyuki, Komatsu Kenji, Kubo Taro, Nukui Akinori, Suzuki Kazumi, Kurokawa Shinsuke, Kobayashi Minoru, Morita Tatsuo
Format: Article
Language:English
Published: BMC 2012-02-01
Series:BMC Urology
Online Access:http://www.biomedcentral.com/1471-2490/12/3

Internet

http://www.biomedcentral.com/1471-2490/12/3

Similar Items